ToxIC Launches New Vaping Associated Lung Injury (VAPI) Supplemental Data Form
Since July 2019, there have been thousands of adolescents and adults with respiratory failure linked to vaping. This epidemic has spread through all 50 states, the District of Columbia and two US territories. This so called “Vaping Associated Pulmonary Injury” (VAPI) or “E-cigarette or vaping product use-associated lung injury” (EVALI) has resulted in over 60 deaths. While the Centers for Disease Control (CDC) and the Food and Drug Administration (FDA) continue to investigate the source of this outbreak, no single agent has been linked to the epidemic of EVALI.
As a medical toxicology community, these cases have presented a new challenge in the management and treatment of acute lung injury. From an epidemiological standpoint, data collection from these cases around the country will broaden our knowledge of this epidemic and could uncover a link to the cause or provide improved criteria for diagnosis. ToxIC investigators are in a unique position to collect bedside data on this public health issue and improve our understanding of this critical toxicological illness.
With input from key members of the FDA and CDC, a VAPI supplemental form for contemporary issues was created within a month of the CDC advisory. It was incorporated into REDCap on October 10, 2019, and has grown quickly since implementation.
The VAPI data collected from participating medical toxicologists is crucial to uncovering the product use patterns, characteristic diagnostics, favorable treatments, and ultimate outcomes of patients affected by this emerging illness.